




Instance: composition-en-0ed39b02c95e206c8989dd94965d2705
InstanceOf: CompositionUvEpi
Title: "Composition for elaprase Package Leaflet"
Description:  "Composition for elaprase Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp0ed39b02c95e206c8989dd94965d2705)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - elaprase"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet:</p>
<ol>
<li>What Elaprase is and what it is used for</li>
<li>What you need to know before you use Elaprase</li>
<li>How to use Elaprase</li>
<li>Possible side effects</li>
<li>How to store Elaprase </li>
<li>Contents of the pack and other information</li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What elaprase is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What elaprase is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Elaprase is used as enzyme replacement therapy to treat children and adults with Hunter syndrome 
(Mucopolysaccharidosis II) when the level of the enzyme iduronate-2-sulfatase in the body is lower 
than normal, helping improve the symptoms of the disease. If you suffer from Hunter syndrome, a 
carbohydrate called glycosaminoglycan which is normally broken down by your body, is not broken 
down and slowly accumulates in various organs in your body. This causes cells to function 
abnormally, thereby causing problems for various organs in your body which can lead to tissue 
destruction and organ malfunction and failure. Typical organs where glycosaminoglycan accumulates 
are spleen, liver, lungs, heart, and connective tissue. In some patients glycosaminoglycan accumulates 
also in the brain. Elaprase contains an active substance called idursulfase which works by acting as a
replacement for the enzyme that is at a low level, thereby breaking down this carbohydrate in affected 
cells.
Enzyme replacement therapy is usually administered as a long-term treatment.</p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take elaprase"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take elaprase"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not use Elaprase
If you have experienced severe or potentially life-threatening allergic-type reactions to idursulfase or 
any of the other ingredients of this medicine (listed in section 6) and these cannot be controlled with 
appropriate medical treatment.
Warnings and precautions
Talk to your doctor or nurse before using this medicine.
If you are treated with Elaprase you may experience side effects during or following an infusion (see 
section 4 Possible side effects). The most common symptoms are itching, rash, hives, fever, headache, 
increased blood pressure, and flushing (redness). Most of the time you can still be given this medicine 
even if these symptoms occur. If you experience an allergic side effect following administration of this 
medicine, you should contact your doctor immediately. You may be given additional medicines such 
as antihistamines and corticosteroids to treat or help prevent allergic-type reactions.
If severe allergic reactions occur, your doctor will stop the infusion immediately, and start giving you 
suitable treatment. You may need to stay in hospital.
The nature of your genotype (a genetic make up of all active genes in human cells, which determines 
one s specific, individual characteristics) may influence your therapeutic response to this medicine, as 
well as your risk of developing antibodies and infusion-related side effects. In individual cases, so-
called  neutralising antibodies  may develop, which may diminish activity of Elaprase and your
response to treatment. The longer term effects of antibody development on response to treatment have 
not been established. Please consult your doctor for additional information.
Keeping a record
In order to improve the traceability of biological medicinal products, the name and batch number of 
the administered product should be clearly recorded by your healthcare professional. Speak with your 
healthcare professional if you are not sure.
Other medicines and Elaprase
There is no known interaction of this medicine with other medicines.
Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other 
medicines.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor or pharmacist for advice before taking this medicine.
Driving and using machines
This medicine has no or negligible influence on the ability to drive and use machines.
Elaprase contains sodium
This medicine contains 11.1 mg sodium (main component of cooking/table salt) in each vial. This is 
equivalent to 0.6% of the recommended maximum daily dietary intake of sodium for an adult.</p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take elaprase"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take elaprase"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not 
sure.
This medicine will be given to you under the supervision of a doctor or nurse who is knowledgeable in 
the treatment of Hunter syndrome or other inherited metabolic disorders.
The recommended dose is an infusion of 0.5 mg (half a milligram) for every kg you weigh
Elaprase has to be diluted in sodium chloride 9 mg/ml (0.9%) solution for infusion before use. After 
dilution this medicine is given through a vein (drip feed). The infusion will normally last for 1 to 
3 hours and will be given every week.
Use in children and adolescents
The recommended dosage in children and adolescents is the same as in adults.
If you use more Elaprase than you should
Consult your doctor if you have an overdose of this medication.
If you forget to use Elaprase
If you have missed an Elaprase infusion, please contact your doctor.
If you have any further questions on the use of this medicine, ask your doctor or nurse.</p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. 
Most side effects are mild to moderate and associated with the infusion, however some side effects 
may be serious. Over time the number of these infusion-associated reactions decreases.
If you have problems breathing, with or without bluish skin, tell your doctor straight away and 
seek immediate medical assistance.
Very common side effects (may affect more than 1 in 10 people) are:</p>
<p>Headache</p>
<p>Flushing (redness)</p>
<p>Shortness of breath, wheezing</p>
<p>Abdominal pain, nausea, vomiting, frequent and/or loose stools</p>
<p>Chest pain</p>
<p>Hives, rash, itching, redness of the skin</p>
<p>Fever</p>
<p>Infusion-related reaction (see section entitled  Warnings and precautions )
Common side effects (may affect up to 1 in 10 people) are:</p>
<p>Dizziness, tremor</p>
<p>Rapid heartbeat, irregular heartbeat, bluish skin</p>
<p>Increased blood pressure, decreased blood pressure</p>
<p>Difficulty breathing, cough, low oxygen levels in your blood</p>
<p>Swollen tongue, indigestion</p>
<p>Pain in the joints</p>
<p>Infusion-site swelling, swelling of the extremities, facial swelling
Uncommon side effects (may affect up to 1 in 100 people) are:</p>
<p>Quickened breathing
Side effects for which frequency is not known (cannot be estimated from available data) are:</p>
<p>Serious allergic reactions
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects you can help provide more information on the 
safety of this medicine.</p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store elaprase"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store elaprase"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The 
expiry date refers to the last day of that month.
Store in a refrigerator (2 C   8 C)
Do not freeze
Do not use this medicine if you notice that there is discolouration or presence of foreign particles.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment.</p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Elaprase contains
The active substance is idursulfase, which is a form of the human enzyme iduronate-2-sulfatase. 
Idursulfase is produced in a human cell line by genetic engineering technology (it involves the 
introduction of genetic information into human cells in the lab, which will then produce the desired 
product).
Each vial of Elaprase contains 6 mg of idursulfase. Each ml contains 2 mg of idursulfase.
The other ingredients are Polysorbate 20, sodium chloride, dibasic sodium phosphate, heptahydrate, 
monobasic sodium phosphate, monohydrate and water for injections.
What Elaprase looks like and contents of the pack
This medicine is a concentrate for solution for infusion. It is supplied in a glass vial as a clear to 
slightly opalescent, colourless solution.
Each vial contains 3 ml of concentrate for solution for infusion.
Elaprase is supplied in pack sizes of 1, 4 and 10 vials per carton. Not all pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer
Marketing Authorisation Holder 
Takeda Pharmaceuticals International AG Ireland Branch
Block 2 Miesian Plaza 
50-58 Baggot Street Lower 
Dublin 2
D02 HWIreland
Manufacturer
Takeda Pharmaceuticals International AG Ireland Branch
Block 2 Miesian Plaza
50-58 Baggot Street Lower
Dublin 2
D02 HWIreland
Shire Pharmaceuticals Ireland Limited
Block 2 &amp; 3 Miesian Plaza
50   58 Baggot Street Lower
Dublin 2
Ireland
For any information about this medicine, please contact the local representative of the Marketing
Authorisation Holder:
Belgi /Belgique/Belgien
Takeda Belgium NV
T l/Tel: +32 2 464 06 medinfoEMEA@takeda.com
Lietuva
Takeda, UAB
Tel: +370 521 09 medinfoEMEA@takeda.com</p>
<p>.: +359 2 958 27 medinfoEMEA@takeda.com 
Luxembourg/Luxemburg
Takeda Belgium NV
T l/Tel: +32 2 464 06 medinfoEMEA@takeda.com
 esk  republika
Takeda Pharmaceuticals Czech Republic s.r.o.
Tel: +420 234 722 medinfoEMEA@takeda.com
Magyarorsz g
Takeda Pharma Kft.
Tel.: +36 1 270 7medinfoEMEA@takeda.com
Danmark
Takeda Pharma A/S
Tlf: +45 46 77 10 medinfoEMEA@takeda.com
Malta
 akeda HELLAS S.A.
Tel: +30 210 6387medinfoEMEA@takeda.com
Deutschland
Takeda GmbH
Tel: +49 (0)800 825 3medinfoEMEA@takeda.com
Nederland
Takeda Nederland B.V.
Tel: +31 20 203 5medinfoEMEA@takeda.com
Eesti
Takeda Pharma AS
Tel: +372 6177 medinfoEMEA@takeda.com
Norge
Takeda AS
Tlf: +47 800 800 medinfoEMEA@takeda.com</p>
<p>akeda    . .
T : +30 210 6387medinfoEMEA@takeda.com
 sterreich
Takeda Pharma Ges.m.b.H. 
Tel: +43 (0) 800-20 80 medinfoEMEA@takeda.com
Espa a
Takeda Farmac utica Espa a S.A.
Tel: +34 917 90 42 medinfoEMEA@takeda.com
Polska
Takeda Pharma Sp. z o.o.
Tel.: +48223062medinfoEMEA@takeda.com
France
Takeda France SAS
T l: + 33 1 40 67 33 medinfoEMEA@takeda.com
Portugal
Takeda Farmac uticos Portugal, Lda.
Tel: + 351 21 120 1medinfoEMEA@takeda.com
Hrvatska
Takeda Pharmaceuticals Croatia d.o.o.
Tel: +385 1 377 88 medinfoEMEA@takeda.com
Rom nia
Takeda Pharmaceuticals SRL
Tel: +40 21 335 03 medinfoEMEA@takeda.com
Ireland
Takeda Products Ireland Ltd
Tel: 1800 937 medinfoEMEA@takeda.com
Slovenija
Takeda Pharmaceuticals farmacevtska dru ba d.o.o.
Tel: + 386 (0) 59 082 medinfoEMEA@takeda.com
 sland
Vistor hf.
S mi: +354 535 7medinfoEMEA@takeda.com
Slovensk  republika
Takeda Pharmaceuticals Slovakia s.r.o.
Tel: +421 (2) 20 602 medinfoEMEA@takeda.com
Italia
Takeda Italia S.p.A.
Tel: +39 06 502medinfoEMEA@takeda.com
Suomi/Finland
Takeda Oy
Puh/Tel: 0800 774 medinfoEMEA@takeda.com</p>
<p>akeda    . .
 : +30 210 6387medinfoEMEA@takeda.com
Sverige
Takeda Pharma AB
Tel: 020 795 medinfoEMEA@takeda.com
Latvija
Takeda Latvia SIA
Tel: +371 67840medinfoEMEA@takeda.com
United Kingdom (Northern Ireland)
Takeda UK Ltd
Tel: +44 (0) 2830 640 medinfoEMEA@takeda.com
This leaflet was last revised in .
This medicine has been authorised under  exceptional circumstances . This means that because of the 
rarity of this disease it has been impossible to get complete information on this medicine.
The European Medicines Agency will review any new information on the medicine every year and this 
leaflet will be updated as necessary.
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-0ed39b02c95e206c8989dd94965d2705
InstanceOf: CompositionUvEpi
Title: "Composition for elaprase Package Leaflet"
Description:  "Composition for elaprase Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp0ed39b02c95e206c8989dd94965d2705)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - elaprase"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen
1. Virkning og anvendelse
2. Det skal De vide, før De får Elaprase
3. Sådan får De Elaprase
4. Bivirkninger
5. Opbevaring
6. Pakningsstørrelser og yderligere oplysninger</p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What elaprase is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What elaprase is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Elaprase bruges som enzymerstatningsbehandling til børn og voksne med Hunter syndrom 
(mukopolysaccharidose II), hvis niveauet af enzymet iduronat-2-sulfatase i kroppen er under det 
normale niveau. Elaprase mindsker sygdommens symptomer. Hvis De lider af Hunters syndrom, vil et 
kulhydrat, der hedder glykosaminoglykan, og som normalt nedbrydes i kroppen, ikke blive nedbrudt 
og vil derfor langsomt ophobes i forskellige celler i kroppen. Det får cellerne til at fungere unormalt. 
Dette skaber problemer i forskellige organer i kroppen, hvilket kan medføre vævsødelæggelse, 
organforstyrrelser og organsvigt. Glykosaminoglykan ophobes typisk i organer som milt, lever, lunger 
og hjerte samt i bindevæv. Hos nogle patienter ophobes glykosaminoglykan også i hjernen. Elaprase 
indeholder et aktivt stof, der hedder idursulfase, og dette stof virker som erstatning for det enzym, der 
er på et lavt niveau, hvorved kulhydratet i de påvirkede celler nedbrydes.
Enzymsubstitutionsbehandling er som regel en langvarig behandling.</p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take elaprase"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take elaprase"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Brug ikke Elaprase
hvis De har haft alvorlige eller muligvis livstruende overfølsomhedsreaktioner på idursulfase eller et 
af de øvrige indholdsstoffer i Elaprase (angivet i punkt 6), og hvis overfølsomhedsreaktionerne ikke 
kan kontrolleres med relevant medicinsk behandling.
Advarsler og forsigtighedsregler
Kontakt lægen eller sundhedspersonalet, før De bruger dette lægemiddel.
23
Hvis De behandles med Elaprase, vil De muligvis opleve nogle bivirkninger under eller efter en 
infusion (se pkt. 4, Bivirkninger). De mest almindelige symptomer er kløe, udslæt, nældefeber, feber, 
hovedpine, forhøjet blodtryk og rødmen (flushing). For det meste kan De alligevel få dette 
lægemiddel, selvom disse symptomer opstår. Hvis De oplever en allergisk bivirkning efter indgivelse 
af dette lægemiddel, skal De straks kontakte Deres læge. De vil muligvis få flere lægemidler, for 
eksempel antihistaminer og kortikosteroider, til at behandle eller hjælpe til at forebygge allergi-
lignende reaktioner.
Hvis alvorlige allergiske reaktioner opstår, vil lægen straks standse infusionen og derefter påbegynde 
en passende behandling til Dem. De vil muligvis skulle blive på hospitalet.
Deres genotype (den genetiske sammensætning af alle aktive gener i humane celler, der afgør den 
enkeltes specifikke, individuelle egenskaber) kan have betydning for, hvordan De reagerer på 
behandlingen med dette lægemiddel, og for risikoen for, at De udvikler antistoffer og 
infusionsrelaterede bivirkninger. I enkelte tilfælde kan der udvikles såkaldt neutraliserende antistoffer, 
som kan mindske Elaprases aktivitet og din reaktion på behandlingen. Den langsigtede effekt, som 
udviklingen af antistoffer kan have på patientens reaktion på behandlingen, er ikke klarlagt. De kan få 
yderligere oplysninger om dette hos Deres læge.
Journalføring
For at forbedre sporbarheden af biologiske lægemidler skal din læge eller sundhedspersonalet tydeligt 
registrere handelsnavnet og batchnummeret på det indgivne lægemiddel. Tal med din læge, hvis du 
ikke er sikker.
Brug af anden medicin sammen med Elaprase
Der findes ingen kendt interaktion mellem dette lægemiddel og andre lægemidler.
Fortæl altid lægen, apoteketspersonalet eller sundhedspersonalet, hvis De bruger anden medicin eller 
har gjort det for nylig.
Graviditet og amning
Hvis De er gravid eller ammer, har mistanke om, at De er gravid, eller planlægger at blive gravid, skal 
De spørge Deres læge eller apotekspersonalet til råds, før De bruger dette lægemiddel.
Trafik- og arbejdssikkerhed
Dette lægemiddel påvirker ikke eller kun i ubetydelig grad evnen til at føre motorkøretøj og betjene 
maskiner.
Elaprase indeholder natrium
Dette lægemiddel indeholder 11,1 mg natrium (hovedkomponent i madlavnings-/bordsalt) i hvert 
hætteglas. Dette svarer til 0,6% af den anbefalede maksimale daglige indtagelse på 2 g natrium for en 
voksen.</p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take elaprase"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take elaprase"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Brug altid Elaprase nøjagtigt efter lægens anvisning. Er De i tvivl, så spørg lægen.
De vil få dette lægemiddel indsprøjtet under overvågning af en læge eller sygeplejerske, der har 
erfaring med behandling af Hunters syndrom eller andre arvelige stofskiftesygdomme.
Den anbefalede dosis er infusion af 0,5 mg (et halvt milligram) for hvert kilogram, De vejer.
24
Elaprase skal fortyndes med natriumchlorid-infusionsvæske 9 mg/ml (0,9 %) inden brug. Efter 
fortynding gives dette lægemiddel i en vene (med drop). Infusionen varer normalt 1 til 3 timer og 
gives hver uge.
Brug til børn og unge
Den anbefalede dosis til børn og unge er den samme som til voksne.
Hvis De har fået for meget Elaprase
Kontakt lægen ved overdosering af dette lægemiddel.
Hvis De har glemt at få Elaprase
Kontakt Deres læge, hvis De ved en fejl ikke har fået Deres infusion med dette lægemiddel.
Spørg lægen, apotekspersonalet eller sundhedspersonalet, hvis der er noget, De er i tvivl om.</p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger.
De fleste bivirkninger er lette til moderate og forbundet med infusionen. Nogle bivirkninger kan dog 
være alvorlige. Med tiden falder antallet af disse infusionsrelaterede virkninger.
Hvis De har problemer med at trække vejret - med eller uden blåfarvning af huden - skal De straks 
informere Deres læge og øjeblikkeligt søge lægehjælp.
Meget almindelige bivirkninger (kan forekomme hos flere end 1 ud af 10 patienter) er:

Hovedpine

Ansigtsrødmen

Stakåndethed, pibende vejrtrækning

Mavesmerter, kvalme, opkastning, hyppig og/eller løs afføring

Brystsmerter

Nældefeber, udslæt, kløe, rødmen af huden

Feber

Infusionsrelaterede reaktioner (se punktet 'Advarsler og forsigtighedsregler')
Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 patienter) er:

Svimmelhed, tremor

Hurtig hjerterytme, uregelmæssig hjerterytme, blåfarvning af huden

Forhøjet blodtryk, nedsat blodtryk

Åndedrætsbesvær, hoste, lavt iltniveau i blodet

Hævet tunge, fordøjelsesbesvær

Smerter i led 

Hævelse på infusionsstedet, hævelse i ben/arme, hævelse i ansigtet 
Kkke almindelige bivirkninger (kan forekomme hos op til 1 ud af 100 patienter) er:

Hurtig vejrtrækning
Bivirkninger, hvis hyppighed ikke kendes (kan ikke vurderes ud fra tilgængelige data):

Alvorlige overfølsomhedsreaktioner
25
Indberetning af bivirkninger
Hvis De oplever bivirkninger, bør De tale med Deres læge, sygeplejerske eller apoteket. Dette gælder 
også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. De eller Deres pårørende kan 
også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan De hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel.</p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store elaprase"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store elaprase"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn.
Brug ikke lægemidlet efter den udløbsdato, der står på pakningen efter Exp. Udløbsdatoen er den 
sidste dag i den nævnte måned.
Opbevares i køleskab (2C - 8C)
Må ikke nedfryses
Brug ikke lægemidlet, hvis De ser misfarvning eller partikler i produktet.
Spørg på apoteket, hvordan De skal bortskaffe medicinrester. Af hensyn til miljøet må De ikke smide 
medicinrester i afløbet, toilettet eller skraldespanden.</p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Elaprase indeholder:
Aktivt stof: idursulfase, som er en form af det humane enzym iduronat-2-sulfatase. Idursulfase 
produceres i en human cellelinje ved hjælp af en genetisk teknologi (genetisk information indføres i 
humane celler i et laboratorium, hvilket får cellerne til at fremstille det ønskede produkt).
Hvert hætteglas med Elaprase indeholder 6 mg idursulfase. Hver ml indeholder 2 mg idursulfase.
Øvrige indholdsstoffer: Polysorbat 20, natriumchlorid, dinatriumphosphatheptahydrat,
natriumdihydrogenphosphatmonohydrat og vand til injektionsvæsker.
Udseende og pakningsstørrelse
Dette lægemiddel er et koncentrat til infusionsvæske, opløsning. Det leveres i et hætteglas som en 
gennemsigtig til let opaliserende farveløs opløsning.
Hvert hætteglas indeholder 3 ml koncentrat til infusionsvæske, opløsning.
Elaprase leveres i pakningsstørrelser med 1, 4 eller 10 hætteglas pr. Karton. Ikke alle 
pakningsstørrelser er nødvendigvis markedsført.
Indehaver af markedsføringstilladelsen og fremstiller
Indehaveren af markedsføringstilladelsen 
Takeda Pharmaceuticals International AG Ireland Branch
Block 2 Miesian Plaza 
50-58 Baggot Street Lower 
Dublin 2
D02 HW68
Irland
26
Fremstiller
Takeda Pharmaceuticals International AG Ireland Branch
Block 2 Miesian Plaza 
50-58 Baggot Street Lower 
Dublin 2
D02 HW68
Irland
Shire Pharmaceuticals Ireland Limited
Block 2 &amp; 3 Miesian Plaza
50 - 58 Baggot Street Lower
Dublin 2
Irland
Hvis De ønsker yderligere oplysninger om dette lægemiddel, skal De henvende Dem til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen:
België/Belgique/Belgien
Takeda Belgium NV
Tél/Tel: +32 2 464 06 11
medinfoEMEA@takeda.com
Lietuva
Takeda, UAB
Tel: +370 521 09 070
medinfoEMEA@takeda.com
България
Такеда България ЕООД
Тел.: +359 2 958 27 36
medinfoEMEA@takeda.com 
Luxembourg/Luxemburg
Takeda Belgium NV
Tél/Tel: +32 2 464 06 11
medinfoEMEA@takeda.com
Česká republika
Takeda Pharmaceuticals Czech Republic s.r.o.
Tel: +420 234 722 722
medinfoEMEA@takeda.com
Magyarország
Takeda Pharma Kft.
Tel.: +36 1 270 7030
medinfoEMEA@takeda.com
Danmark
Takeda Pharma A/S
Tlf: +45 46 77 10 10
medinfoEMEA@takeda.com
Malta
Τakeda HELLAS S.A.
Tel: +30 210 6387800
medinfoEMEA@takeda.com
Deutschland
Takeda GmbH
Tel: +49 (0)800 825 3325
medinfoEMEA@takeda.com
Nederland
Takeda Nederland B.V.
Tel: +31 20 203 5492
medinfoEMEA@takeda.com
Eesti
Takeda Pharma AS
Tel: +372 6177 669
medinfoEMEA@takeda.com
Norge
Takeda AS
Tlf: +47 800 800 30
medinfoEMEA@takeda.com
Ελλάδα
Τakeda ΕΛΛΑΣ Α.Ε.
Tηλ: +30 210 6387800
medinfoEMEA@takeda.com
Österreich
Takeda Pharma Ges.m.b.H. 
Tel: +43 (0) 800-20 80 medinfoEMEA@takeda.com
España
Takeda Farmacéutica España S.A.
Tel: +34 917 90 42 22
medinfoEMEA@takeda.com
Polska
Takeda Pharma Sp. z o.o.
Tel.: +48223062447
medinfoEMEA@takeda.com
27
France
Takeda France SAS
Tél: + 33 1 40 67 33 00
medinfoEMEA@takeda.com
Portugal
Takeda Farmacêuticos Portugal, Lda.
Tel: + 351 21 120 1457
medinfoEMEA@takeda.com
Hrvatska
Takeda Pharmaceuticals Croatia d.o.o.
Tel: +385 1 377 88 96
medinfoEMEA@takeda.com
România
Takeda Pharmaceuticals SRL
Tel: +40 21 335 03 91
medinfoEMEA@takeda.com
Ireland
Takeda Products Ireland Ltd
Tel: 1800 937 970
medinfoEMEA@takeda.com
Slovenija
Takeda Pharmaceuticals farmacevtska družba d.o.o.
Tel: + 386 (0) 59 082 480
medinfoEMEA@takeda.com
Ísland
Vistor hf.
Sími: +354 535 7000
medinfoEMEA@takeda.com
Slovenská republika
Takeda Pharmaceuticals Slovakia s.r.o.
Tel: +421 (2) 20 602 600
medinfoEMEA@takeda.com
Italia
Takeda Italia S.p.A.
Tel: +39 06 502601
medinfoEMEA@takeda.com
Suomi/Finland
Takeda Oy
Puh/Tel: 0800 774 051
medinfoEMEA@takeda.com
Κύπρος
Τakeda ΕΛΛΑΣ Α.Ε.
Τηλ: +30 210 6387800
medinfoEMEA@takeda.com
Sverige
Takeda Pharma AB
Tel: 020 795 079
medinfoEMEA@takeda.com
Latvija
Takeda Latvia SIA
Tel: +371 67840082
medinfoEMEA@takeda.com
United Kingdom (Northern Ireland)
Takeda UK Ltd
Tel: +44 (0) 2830 640 902
medinfoEMEA@takeda.com
Denne indlægsseddel blev senest ændret .
Dette lægemiddel er godkendt under "særlige omstændigheder". Det betyder, at det ikke har været 
muligt at opnå fuldstændig dokumentation for lægemidlet, fordi det anvendes til en sjælden sygdom.
Det Europæiske Lægemiddelagentur vil hvert år vurdere nye oplysninger om lægemidlet, og denne 
indlægsseddel vil om nødvendigt blive ajourført.
Andre informationskilder
De kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu/. Der er også links til andre websteder om sjældne sygdomme 
og om, hvordan de behandles.
Denne indlægsseddel findes på alle EU-/EØS-sprog på Det Europæiske Lægemiddelagenturs 
hjemmeside.</p>
<hr />
<p>28
Nedenstående oplysninger er til læger og sundhedspersonale:
Instruktioner vedrørende anvendelse og håndtering samt bortskaffelse
1. Beregn den samlede dosis, der skal indgives, samt det antal hætteglas med Elaprase, der er 
behov for.
2. Fortynd den samlede mængde Elaprase koncentrat til infusionsvæske, opløsning, der er 
nødvendig, i 100 ml natriumchloridinfusionsvæske 9 mg/ml (0,9 %). Det anbefales at bruge et 
0,2 µm inline-filter ved administration af det samlede infusionsvolumen. Der skal udvises 
forsigtighed for at sikre, at de klargjorte opløsninger er sterile, da Elaprase ikke indeholder 
konserveringsmiddel eller et bakteriostatisk middel. En aseptisk teknik skal følges. Efter 
fortynding skal opløsningen blandes forsigtigt, men ikke omrystes.
3. Infusionsvæsken skal inspiceres visuelt for partikler og misfarvning inden administration. Må 
ikke omrystes.
4. Det anbefales, at infusionsvæsken indgives så hurtigt som muligt efter fortynding. Kemisk og 
fysisk stabilitet af den fortyndede opløsning er påvist i 8 timer ved 25°C.
5. Elaprase må ikke infunderes samtidigt med andre lægemidler i den samme intravenøse slange.
6. Kun til engangsbrug. Ikke anvendt lægemiddel samt affald heraf skal bortskaffes i henhold til 
lokale retningslinjer.</p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-0ed39b02c95e206c8989dd94965d2705
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for elaprase Package Leaflet for language en"
Description: "ePI document Bundle for elaprase Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-0ed39b02c95e206c8989dd94965d2705"
* entry[0].resource = composition-en-0ed39b02c95e206c8989dd94965d2705

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp0ed39b02c95e206c8989dd94965d2705"
* entry[=].resource = mp0ed39b02c95e206c8989dd94965d2705
                            
                    
Instance: bundlepackageleaflet-da-0ed39b02c95e206c8989dd94965d2705
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for elaprase Package Leaflet for language da"
Description: "ePI document Bundle for elaprase Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-0ed39b02c95e206c8989dd94965d2705"
* entry[0].resource = composition-da-0ed39b02c95e206c8989dd94965d2705

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp0ed39b02c95e206c8989dd94965d2705"
* entry[=].resource = mp0ed39b02c95e206c8989dd94965d2705
                            
                    



Instance: mp0ed39b02c95e206c8989dd94965d2705
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Elaprase 2 mg/ml concentrate for solution for infusion"
Description: "Elaprase 2 mg/ml concentrate for solution for infusion"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/06/365/001-003"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Elaprase 2 mg/ml concentrate for solution for infusion"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 0ed39b02c95e206c8989dd94965d2705ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "elaprase"

* status = #current
* mode = #working

* title = "List of all ePIs associated with elaprase"

* subject = Reference(mp0ed39b02c95e206c8989dd94965d2705)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#elaprase "elaprase"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-0ed39b02c95e206c8989dd94965d2705) // elaprase en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-0ed39b02c95e206c8989dd94965d2705) // elaprase da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-0ed39b02c95e206c8989dd94965d2705
InstanceOf: List

* insert 0ed39b02c95e206c8989dd94965d2705ListRuleset
    